Resorcinolnaphthalein | CAS#41307-63-5 | ACE2 activator

Resorcinolnaphthalein
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 463717

CAS#: 41307-63-5

Description: Resorcinolnaphthalein is an Angiotensin-converting enzyme 2 (ACE2) activator, acting as a modulator on RAAS and KKS activation during COVID-19.

Chemical Structure

Resorcinolnaphthalein

CAS# 41307-63-5

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 463717
Name: Resorcinolnaphthalein
CAS#: 41307-63-5
Chemical Formula: C24H14O5
Exact Mass: 382.08
Molecular Weight: 382.370
Elemental Analysis: C, 75.39; H, 3.69; O, 20.92

Price and Availability

Size	Price	Availability
25mg	USD -2	2 Weeks
200mg	USD -2	2 Weeks
500mg	USD -2	2 Weeks
1g	USD -2	2 Weeks
2g	USD -2	2 Weeks
5mg	USD 200	2 Weeks
10mg	USD 320	2 Weeks
50mg	USD 580	2 Weeks
100mg	USD 870	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Resorcinolnaphthalein; NSC-354317; NSC354317; NSC 354317;

IUPAC/Chemical Name: 3',6'-dihydroxy-3H-spiro[benzo[de]isochromene-1,9'-xanthen]-3-one

InChi Key: FTUOFHGOGJGQAB-UHFFFAOYSA-N

InChi Code: InChI=1S/C24H14O5/c25-14-7-9-17-20(11-14)28-21-12-15(26)8-10-18(21)24(17)19-6-2-4-13-3-1-5-16(22(13)19)23(27)29-24/h1-12,25-26H

SMILES Code: O=C(OC12C3=C(OC4=C2C=CC(O)=C4)C=C(O)C=C3)C5=CC=CC6=C5C1=CC=C6

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	Resorcinolnaphthalein increases the activity of ACE2 in vitro (EC50 = 19.5 μM). The activation of ACE2 in rats decreases blood pressure and improves cardiac function. In spontaneously hypertensive rats it produces a reversal of myocardial, perivascular, and renal fibrosis.
In vitro activity:	In vitro assays revealed that resorcinolnaphthalein enhanced ACE2 activity in a dose-dependent manner. Compounds that activate ACE2 lead to decreased blood pressure and the reversal of tissue remodeling. Administration of ACE2 activators has potential for antihypertensive therapy. Reference: Hypertension. 2008 May;51(5):1312-7. https://pubmed.ncbi.nlm.nih.gov/18391097/
In vivo activity:	Resorcinolnaphthalein significantly reduced the severity of acute lung injury (ALI) and pyroptosis in a mice model of ALI. Additionally, resorcinolnaphthalein significantly decreased NLRP3 levels. NLRP3 knockout significantly reduced the severity of ALI and pyroptosis. Reference: Arch Biochem Biophys. 2020 Oct 30;693:108562. https://pubmed.ncbi.nlm.nih.gov/32866470/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMSO	30.0	78.46
	DMF	30.0	78.46
	Ethanol	20.0	52.31

Preparing Stock Solutions

The following data is based on the product molecular weight 382.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Hernández Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RA, Castellano RK, Lampkins AJ, Gubala V, Ostrov DA, Raizada MK. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008 May;51(5):1312-7. doi: 10.1161/HYPERTENSIONAHA.107.108944. Epub 2008 Apr 7. PMID: 18391097. 2. Huang H, Wang J, Liu Z, Gao F. The angiotensin-converting enzyme 2/angiotensin (1-7)/mas axis protects against pyroptosis in LPS-induced lung injury by inhibiting NLRP3 activation. Arch Biochem Biophys. 2020 Oct 30;693:108562. doi: 10.1016/j.abb.2020.108562. Epub 2020 Aug 28. PMID: 32866470. 3. Li G, Zhang H, Zhao L, Zhang Y, Yan D, Liu Y. Angiotensin-converting enzyme 2 activation ameliorates pulmonary endothelial dysfunction in rats with pulmonary arterial hypertension through mediating phosphorylation of endothelial nitric oxide synthase. J Am Soc Hypertens. 2017 Dec;11(12):842-852. doi: 10.1016/j.jash.2017.10.009. Epub 2017 Oct 28. PMID: 29146157.
In vitro protocol:	1. Hernández Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RA, Castellano RK, Lampkins AJ, Gubala V, Ostrov DA, Raizada MK. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008 May;51(5):1312-7. doi: 10.1161/HYPERTENSIONAHA.107.108944. Epub 2008 Apr 7. PMID: 18391097.
In vivo protocol:	1. Huang H, Wang J, Liu Z, Gao F. The angiotensin-converting enzyme 2/angiotensin (1-7)/mas axis protects against pyroptosis in LPS-induced lung injury by inhibiting NLRP3 activation. Arch Biochem Biophys. 2020 Oct 30;693:108562. doi: 10.1016/j.abb.2020.108562. Epub 2020 Aug 28. PMID: 32866470. 2. Li G, Zhang H, Zhao L, Zhang Y, Yan D, Liu Y. Angiotensin-converting enzyme 2 activation ameliorates pulmonary endothelial dysfunction in rats with pulmonary arterial hypertension through mediating phosphorylation of endothelial nitric oxide synthase. J Am Soc Hypertens. 2017 Dec;11(12):842-852. doi: 10.1016/j.jash.2017.10.009. Epub 2017 Oct 28. PMID: 29146157.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Huang H, Wang J, Liu Z, Gao F. The angiotensin-converting enzyme 2/angiotensin (1-7)/mas axis protects against pyroptosis in LPS-induced lung injury by inhibiting NLRP3 activation. Arch Biochem Biophys. 2020 Oct 30;693:108562. doi: 10.1016/j.abb.2020.108562. Epub 2020 Aug 28. PMID: 32866470.

2: Li Y, Zhou W, Yang L, You R. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. Pharmacol Res. 2020 Jul;157:104833. doi: 10.1016/j.phrs.2020.104833. Epub 2020 Apr 14. PMID: 32302706; PMCID: PMC7194807.

3: Zhang X, Zheng J, Yan Y, Ruan Z, Su Y, Wang J, Huang H, Zhang Y, Wang W, Gao J, Chi Y, Lu X, Liu Z. Angiotensin-converting enzyme 2 regulates autophagy in acute lung injury through AMPK/mTOR signaling. Arch Biochem Biophys. 2019 Sep 15;672:108061. doi: 10.1016/j.abb.2019.07.026. Epub 2019 Jul 26. PMID: 31356776.

4: Yan D, Li G, Zhang Y, Liu Y. Angiotensin-converting enzyme 2 activation suppresses pulmonary vascular remodeling by inducing apoptosis through the Hippo signaling pathway in rats with pulmonary arterial hypertension. Clin Exp Hypertens. 2019;41(6):589-598. doi: 10.1080/10641963.2019.1583247. Epub 2019 Feb 26. PMID: 30806090.

5: Li G, Zhang H, Zhao L, Zhang Y, Yan D, Liu Y. Angiotensin-converting enzyme 2 activation ameliorates pulmonary endothelial dysfunction in rats with pulmonary arterial hypertension through mediating phosphorylation of endothelial nitric oxide synthase. J Am Soc Hypertens. 2017 Dec;11(12):842-852. doi: 10.1016/j.jash.2017.10.009. Epub 2017 Oct 28. PMID: 29146157.

6: Li G, Liu Y, Zhu Y, Liu A, Xu Y, Li X, Li Z, Su J, Sun L. ACE2 activation confers endothelial protection and attenuates neointimal lesions in prevention of severe pulmonary arterial hypertension in rats. Lung. 2013 Aug;191(4):327-36. doi: 10.1007/s00408-013-9470-8. Epub 2013 May 8. PMID: 23652350.

7: Li G, Xu YL, Ling F, Liu AJ, Wang D, Wang Q, Liu YL. Angiotensin-converting enzyme 2 activation protects against pulmonary arterial hypertension through improving early endothelial function and mediating cytokines levels. Chin Med J (Engl). 2012 Apr;125(8):1381-8. PMID: 22613639.

8: Hernández Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RA, Castellano RK, Lampkins AJ, Gubala V, Ostrov DA, Raizada MK. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008 May;51(5):1312-7. doi: 10.1161/HYPERTENSIONAHA.107.108944. Epub 2008 Apr 7. PMID: 18391097.

Your view history

Resorcinolnaphthalein featured